Trimeris, Inc and Array BioPharma Inc announced the renewal of an agreement to discover small molecule entry inhibitors directed against human immunodeficiency virus (HIV).

According to the deal, Trimeris will screen small molecule compounds created by Array against HIV entry inhibitor targets. The terms of the agreement are substantially similar to those of the initial agreement, signed in August 2001. Array will be entitled to receive research funding as well as payments and royalties based on the success of this program.

"Trimeris is pleased to extend the research agreement with Array which supplements our small molecule research program," commented Dani Bolognesi, chief executive officer and chief scientific officer at Trimeris.

Trimeris Inc is a biopharmaceutical company engaged in the development novel therapeutic agents for the treatment of viral disease.